Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hybrigenics has released preclinical trial results of a study evaluating inecalcitol which showed that the product inhibits the proliferation of human cancer cells in-vitro, as well as the growth of hormone-dependent prostate cancer xenografts in-vivo in mice.
Subscribe to our email newsletter
In the trial, inecalcitol was 11 times potent than a naturally active metabolite of vitamin D, calcitriol in suppressing the growth in-vitro of the human hormone-dependent prostate cancer cell line named LNCaP
The company said inecalcitol was dosed at 1.3mg/kg by intraperitoneal injection three times per week for 42 days to nude mice bearing LNCaP xenografts in the trial.
The results of the trial also suggested that, in-vivo, inecalcitol was 480 times less toxic than calcitriol in mice.